Status:

COMPLETED

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Lead Sponsor:

GlaxoSmithKline

Conditions:

Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

Eligibility:

All Genders

20-79 years

Phase:

PHASE1

Brief Summary

This is an open-label study to evaluate safety, tolerability, efficacy and PK profile of ofatumumab monotherapy in Japanese follicular lymphoma (FL) or chronic lymphocytic leukemia (CLL) patients. sub...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Signed Informed Consent.
  • Histologically confirmed relapsed or refractory CD20 positive FL grade 1-3a and 1 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or CD5, CD19, CD20 and CD23 positive relapse or refractory CLL.
  • Subjects must have adequate blood, liver, and kidney function.
  • Subjects who passed the provided periods from the last anti-cancer treatments at screening
  • ECOG Performance Status of 0-2
  • Life expectancy more than 24 weeks at screening
  • EXCLUSION CRITERIA:
  • Current and past malignancy other than FL and CLL within 5 years prior to screening.
  • Known Richter's transformation
  • Previous autologous stem cell transplantation within 24 weeks prior to screening
  • Previous allogeneic stem cell transplantation
  • Known CNS involvement
  • History of significant cerebrovascular disease
  • Current cardiac disease requiring medical treatment
  • Chronic or ongoing active infectious disease requiring systemic treatment
  • Patients with pleural effusion or ascites detectable by physical examination
  • Positive serology test for any of HBsAg, anti-HBc or anti-HCV
  • Known HIV positive
  • Pregnant or lactating women
  • Women of childbearing potential and male patients not willing to use adequate contraception

Exclusion

    Key Trial Info

    Start Date :

    September 19 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 18 2009

    Estimated Enrollment :

    6 Patients enrolled

    Trial Details

    Trial ID

    NCT00742144

    Start Date

    September 19 2008

    End Date

    November 18 2009

    Last Update

    November 17 2017

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    GSK Investigational Site

    Aichi, Japan, 466-8650

    2

    GSK Investigational Site

    Tokyo, Japan, 104-0045

    3

    GSK Investigational Site

    Tokyo, Japan, 135-8550